Epigenetic & Genomics
Epigenetic & Genomics
批准号:
10176469
负责人:
SVEN W HEINZ
金额:
$19.75万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
未结题
起止时间:
2002-12-01 至 2025-06-30
关键词:
ATAC-seqBioinformaticsBiological AssayCRISPR screenCellsChIP-seqChromatinChromiumComputational BiologyConsultationsData AnalysesDevelopmentDiabetes MellitusEndocrinologyEpigenetic ProcessEquipmentExperimental DesignsGene ExpressionGenesGenetic TranscriptionGenomic medicineGenomicsGoalsHi-CHigh-Throughput Nucleotide SequencingImmunoprecipitationInfrastructureInstitutesLinkMassive Parallel SequencingMetagenomicsMethodologyMolecular GeneticsPostdoctoral FellowProductivityQuality ControlResearchResearch PersonnelResource SharingServicesSignal TransductionSignal Transduction PathwaySpecialistTechnologyTrainingTraining and EducationTransposaseTreatment Protocolsbasechromatin immunoprecipitationcostcost effectivenesscrosslinkcrosslinking and immunoprecipitation sequencingdata qualitydeep sequencingdiabetes pathogenesisdisease phenotypeepigenomeepigenomicsfunctional genomicsgenome sequencinggenomic dataglobal run on sequencinghigh throughput analysisinnovationmiRNA expression profilingnew technologyprogramsrecruitresponseribosome profilingsequencing platformsingle cell sequencingstudent trainingtechnology validationtranscriptome sequencingtranscriptomicstreatment strategywhole genome
中文摘要
核心C项目摘要
糖尿病研究的一个主要目标是了解表观基因组的改变和随后的基因突变是如何影响糖尿病的。
基因表达的应答影响疾病表型和治疗方案。的目的
表观遗传学和基因组学核心(EGC)是提供尖端,可靠和创新的基因组技术
支持DRC研究者的糖尿病及相关内分泌学和代谢研究目标。它还
提供基因组技术方面的培训、教育和咨询,以提高DRC的能力。
研究人员在他们的研究中实施这些技术。小组委员会将提供以下服务:
基于测序的检测技术支持:核心将提供高水平的技术支持,
在Illumina测序平台(MiSeq、HiSeq 2500、HiSeq 4000、NovaSeq)上的通量测序测定
6000),实现RNA测序(RNA-seq),低输入RNA-seq,microRNA测序(miRNAseq),全球
运行测序(GRO-Seq),核糖体分析和深度测序(Ribo-Seq),染色质
免疫沉淀连接大规模平行测序(ChIP-Seq),转座酶可重复性测定
染色质高通量测序(ATAC-Seq),交联免疫沉淀(CLIP-Seq),Hi-C,
甲基C测序、宏基因组测定和CRISPR筛选的测序。
单细胞测序测定:核心将为单细胞测序测定提供技术支持,
包括10 X Genomics Chromium单细胞解决方案技术,以及新技术的实施
当他们出现。
培训和咨询:核心将提供咨询和培训的学生,博士后研究员,
在高通量测序方法学和数据分析方面向研究人员和技术人员提供咨询。
这些功能将由功能基因组学专家监督。
生物信息学支持:核心将提供生物信息学支持,
设计、技术平台选择、数据分析和数据质量控制。
英文摘要
Project Summary Core C
A major goal in diabetes research is to understand how alterations in the epigenome and subsequent
responses in gene expression impact disease phenotype and treatment regimens. The objective of the
Epigenetic and Genomics Core (EGC) is to provide cutting-edge, reliable and innovative genomic technologies
to support the diabetes and related endocrinology and metabolism research goals of DRC investigators. It also
offers training, education and consultation in genomics technologies in order to enhance the ability of DRC
Investigators to implement these technologies in their research. The EGC will provide the following services:
Technical Support For Sequencing-Based Assays: The Core will provide technical support for high-
throughput sequencing assays on Illumina sequencing platforms (MiSeq, HiSeq2500, HiSeq4000, NovaSeq
6000), enabling RNA sequencing (RNA-seq), low-input RNA-seq, microRNA sequencing (miRNAseq), Global
Run- On sequencing (GRO-Seq), ribosome profiling and deep sequencing (Ribo-Seq), Chromatin
Immunoprecipitation linked to massively parallel sequencing (ChIP-Seq), Assay for Transposase- Accessible
Chromatin with high throughput sequencing (ATAC-Seq), Cross-Linking Immunoprecipitation (CLIP-Seq), Hi-C,
MethylC-sequencing, metagenomic assays, and sequencing of CRISPR Screens.
Single Cell Sequencing Assays: The Core will provide technical support for single cell sequencing assays,
including 10X Genomics Chromium Single Cell Solution technologies, and implementation of new technologies
as they arise.
Training and Consultation: The Core will provide consultation and training of students, postdoctoral fellows,
investigators and technical staff regarding high-throughput sequencing methodologies and data analysis.
These functions will be overseen by the Functional Genomics Specialist.
Bioinformatics Support: The Core will provide bioinformatics support for assistance with experimental
design, choice of technological platform, data analysis and data quality control.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
How transcription disrupts genome 3D organization
-
批准号:10390097
-
项目类别:
-
资助金额:$3.6万
-
财政年份:2020
-
负责人:SVEN W HEINZ
-
依托单位:
How transcription disrupts genome 3D organization
-
批准号:9888261
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2020
-
负责人:SVEN W HEINZ
-
依托单位:
How transcription disrupts genome 3D organization
-
批准号:10312025
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2020
-
负责人:SVEN W HEINZ
-
依托单位:
How transcription disrupts genome 3D organization
-
批准号:10078952
-
项目类别:
-
资助金额:$31.55万
-
财政年份:2020
-
负责人:SVEN W HEINZ
-
依托单位:
How transcription disrupts genome 3D organization
-
批准号:10538566
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2020
-
负责人:SVEN W HEINZ
-
依托单位:
Molecular and genetic analysis of DP103
-
批准号:7388184
-
项目类别:
-
资助金额:$5.2万
-
财政年份:2006
-
负责人:SVEN W HEINZ
-
依托单位:
Molecular and genetic analysis of DP103
-
批准号:7056323
-
项目类别:
-
资助金额:$5.04万
-
财政年份:2006
-
负责人:SVEN W HEINZ
-
依托单位:
Epigenetic & Genomics
-
批准号:10454982
-
项目类别:
-
资助金额:$19.58万
-
财政年份:2002
-
负责人:SVEN W HEINZ
-
依托单位:
海外基金